Login Register Cart 0
Generic placeholder image

Clinical Cancer Drugs

Editor-in-Chief

ISSN (Print): 2212-697X
ISSN (Online): 2212-6988

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy of Gefitinib in Patients with Advanced Non-small-cell Carcinoma of the Lung Harboring Common, Uncommon and Complex EGFR Mutations

Author(s): Wang Chun Kwok*, Ka Yan Chiang, James Chung Man Ho, Terence Chi Chun Tam, Mary Sau Man Ip and David Chi Leung Lam

Volume 8, Issue 2, 2021

Published on: 01 December, 2021

Article ID: e291021197489 Pages: 9

DOI: 10.2174/2212697X08666211029142257

Price: $65

Abstract

Background: As the commonest EGFR-TKI being used in Hong Kong, gefitinib has shown to be efficacious and safe as first-line treatment for L858R mutation and exon 19 deletions with less gastrointestinal and cutaneous adverse events than erlotinib and afatinib. The evidence for therapeutic efficacy for uncommon and complex EGFR mutations, on the other hand, is lacking. It is important to explore whether or not gefitinib is helpful for uncommon and complex EGFR mutations.

Objectives: To assess the therapeutic efficacy of gefitinib, as measured by progression-free survival and overall survival, among advanced-stage lung cancer patients with common, uncommon, and complex EGFR mutations.

Methods: This retrospective cohort study included 241 Chinese patients with advanced non-smallcell carcinoma of the lung harboring EGFR mutations and received gefitinib 250 mg daily as firstline treatment. The progression-free survival (PFS) and overall survival (OS) for patients with different EGFR mutations, namely exon 19 deletions, L858R mutation in exon 21, uncommon EGFR mutations, and complex EGFR mutations, were analyzed.

Results: Among the 241 patients, 118 (49%) had exon 19 deletion, 104 (43%) had L858R mutation in exon 21, 6 (2.5%) had uncommon EGFR mutations, and 13 (5.4%) had complex EGFR mutations. The mean age was 69. 72% of the patients were female, and 81% were non-smokers. Patients with complex EGFR mutations, regardless of the presence of exon 19 deletion and L858R mutation as the component, have better PFS and OS than patients with single common EGFR mutations (Exon 19 deletion or L858R mutation). Patients with uncommon EGFR mutations have inferior PFS and OS than those with common EGFR mutations.

Conclusion: Gefitinib is a possible option for patients with complex EGFR mutations, while it may not be the preferred treatment option in patients with single uncommon EGFR mutations.

Keywords: Non-small cell carcinoma, gefitinib, EGFR tyrosine kinase inhibitor, EGFR mutations, uncommon EGFR mutations, complex EGFR mutations.

Graphical Abstract

[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[2]
Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019; 94(8): 1623-40.
[http://dx.doi.org/10.1016/j.mayocp.2019.01.013] [PMID: 31378236]
[3]
Walters S, Maringe C, Coleman MP, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: A population-based study, 2004-2007. Thorax 2013; 68(6): 551-64.
[http://dx.doi.org/10.1136/thoraxjnl-2012-202297] [PMID: 23399908]
[4]
Mohammad N, Singh SV, Malvi P, et al. Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex. Sci Rep 2015; 5: 11853.
[http://dx.doi.org/10.1038/srep11853] [PMID: 26149967]
[5]
Muhammad N, Steele R, Isbell TS, Philips N, Ray RB. Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death. Oncotarget 2017; 8(39): 66226-36.
[http://dx.doi.org/10.18632/oncotarget.19887] [PMID: 29029506]
[6]
Federico C, Sun J, Muz B, et al. Localized delivery of cisplatin to cervical cancer improves its therapeutic efficacy and minimizes its side effect profile. Int J Radiat Oncol Biol Phys 2021; 109(5): 1483-94.
[http://dx.doi.org/10.1016/j.ijrobp.2020.11.052] [PMID: 33253820]
[7]
Rashmi R, Jayachandran K, Zhang J, et al. Glutaminase inhibitors induce thiol-mediated oxidative stress and radiosensitization in treatment-resistant cervical cancers. Mol Cancer Ther 2020; 19(12): 2465-75.
[PMID: 33087507]
[8]
Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9(2): 154-62.
[http://dx.doi.org/10.1097/JTO.0000000000000033] [PMID: 24419411]
[9]
Kawaguchi T, Koh Y, Ando M, et al. Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung cancer study. J Clin Oncol 2016; 34(19): 2247-57.
[http://dx.doi.org/10.1200/JCO.2015.64.2322] [PMID: 27161973]
[10]
Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol 2012; 30(27): 3330-6.
[http://dx.doi.org/10.1200/JCO.2012.43.1858] [PMID: 22753908]
[11]
Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29(21): 2866-74.
[http://dx.doi.org/10.1200/JCO.2010.33.4235] [PMID: 21670455]
[12]
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361(10): 947-57.
[http://dx.doi.org/10.1056/NEJMoa0810699] [PMID: 19692680]
[13]
Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362(25): 2380-8.
[http://dx.doi.org/10.1056/NEJMoa0909530] [PMID: 20573926]
[14]
Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: Quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012; 17(6): 863-70.
[http://dx.doi.org/10.1634/theoncologist.2011-0426] [PMID: 22581822]
[15]
Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 2015; 16(7): 830-8.
[http://dx.doi.org/10.1016/S1470-2045(15)00026-1] [PMID: 26051236]
[16]
Yang JC, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases. J Thorac Oncol 2020; 15(5): 803-15.
[http://dx.doi.org/10.1016/j.jtho.2019.12.126] [PMID: 31931137]
[17]
Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol 2020; 38(5): 488-95.
[http://dx.doi.org/10.1200/JCO.19.00931] [PMID: 31825714]
[18]
Floc’h N, Lim S, Bickerton S, et al. Osimertinib, an irreversible next-generation egfr tyrosine kinase inhibitor, exerts antitumor activity in various preclinical nsclc models harboring the uncommon egfr mutations G719X or L861Q or S768I. Mol Cancer Ther 2020; 19(11): 2298-307.
[http://dx.doi.org/10.1158/1535-7163.MCT-20-0103] [PMID: 32943544]
[19]
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020; 382(1): 41-50.
[http://dx.doi.org/10.1056/NEJMoa1913662] [PMID: 31751012]
[20]
Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated egfr-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378(2): 113-25.
[http://dx.doi.org/10.1056/NEJMoa1713137] [PMID: 29151359]
[21]
Watanabe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol 2014; 9(2): 189-94.
[http://dx.doi.org/10.1097/JTO.0000000000000048] [PMID: 24419415]
[22]
Chiu CH, Yang CT, Shih JY, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol 2015; 10(5): 793-9.
[http://dx.doi.org/10.1097/JTO.0000000000000504] [PMID: 25668120]
[23]
Krawczyk P, Kowalski DM, Ramlau R, et al. Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations. Oncol Lett 2017; 13(6): 4433-44.
[http://dx.doi.org/10.3892/ol.2017.5980] [PMID: 28599445]
[24]
Kozlov V, Karpov I, Kovalenko S, Shamanin V. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: A case report. Exp Oncol 2017; 39(2): 155-6.
[http://dx.doi.org/10.31768/2312-8852.2017.39(2):155-156] [PMID: 29483495]
[25]
Huang J, Wang Y, Zhai Y, Wang J. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report. Thorac Cancer 2018; 9(6): 745-9.
[http://dx.doi.org/10.1111/1759-7714.12637] [PMID: 29673089]
[26]
Yu G, Xie X, Sun D, et al. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. Int J Clin Exp Pathol 2015; 8(7): 8603-6.
[PMID: 26339441]
[27]
Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 2010; 40(11): 1105-9.
[http://dx.doi.org/10.1093/jjco/hyq087] [PMID: 20522446]
[28]
Mompradé E, Arriola E, Martínez-Avilés L. Two rare exon 21 EGFR mutations in patients treated with gefitinib. J Thorac Oncol 2013; 8(4): e36-7.
[http://dx.doi.org/10.1097/JTO.0b013e318286cf9e] [PMID: 23486275]
[29]
Demierre N, Zoete V, Michielin O, et al. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? Lung Cancer 2013; 80(1): 81-4.
[http://dx.doi.org/10.1016/j.lungcan.2012.11.013] [PMID: 23380224]
[30]
Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013; 8(1): 45-51.
[http://dx.doi.org/10.1097/JTO.0b013e3182781e35] [PMID: 23242437]
[31]
Peng L, Song ZG, Jiao SC. Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Sci Rep 2014; 4: 6104.
[http://dx.doi.org/10.1038/srep06104] [PMID: 25130612]
[32]
Keam B, Kim DW, Park JH, et al. Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer. Int J Clin Oncol 2014; 19(4): 594-600.
[http://dx.doi.org/10.1007/s10147-013-0602-1] [PMID: 23912954]
[33]
Kuiper JL, Hashemi SM, Thunnissen E, et al. Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer 2016; 115(12): 1504-12.
[http://dx.doi.org/10.1038/bjc.2016.372] [PMID: 27875527]
[34]
Tam IY, Leung EL, Tin VP, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther 2009; 8(8): 2142-51.
[http://dx.doi.org/10.1158/1535-7163.MCT-08-1219] [PMID: 19671738]
[35]
Asahina H, Yamazaki K, Kinoshita I, Yokouchi H, Dosaka-Akita H, Nishimura M. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 2006; 54(3): 419-22.
[http://dx.doi.org/10.1016/j.lungcan.2006.09.005] [PMID: 17045698]
[36]
Yang JC, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16(2): 141-51.
[http://dx.doi.org/10.1016/S1470-2045(14)71173-8] [PMID: 25589191]
[37]
Kwok WC, Tam TCC, Lam DCL. First reported case of afatinib-associated toxic megacolon. Respirol Case Rep 2018; 6(7): e00360.
[http://dx.doi.org/10.1002/rcr2.360] [PMID: 30186606]

Rights & Permissions Print Cite
Article Metrics
35
1
© 2024 Bentham Science Publishers | Privacy Policy